既往吸烟暴露和慢性阻塞性肺疾病合并症对重度哮喘患者单克隆抗体治疗反应的影响。
Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma.
作者信息
Morobeid Heba, Pizarro Carmen, Biener Leonie, Ulrich-Merzenich Gudrun, Kütting Daniel, Nickenig Georg, Skowasch Dirk
机构信息
Dept of Internal Medicine II - Pneumology/Cardiology, University Hospital Bonn, Bonn, Germany.
These authors contributed equally.
出版信息
ERJ Open Res. 2021 Aug 16;7(3). doi: 10.1183/23120541.00190-2021. eCollection 2021 Jul.
Abstract
摘要
https://bit.ly/3fYC8tC. （此为链接，无法准确翻译其内容，保留原文链接形式）
相似文献
1
Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma.
ERJ Open Res. 2021 Aug 16;7(3). doi: 10.1183/23120541.00190-2021. eCollection 2021 Jul.
2
Consistency and reliability of smoking-related variables: longitudinal study design in asthma and COPD.
Eur Clin Respir J. 2019 Apr 11;6(1):1591842. doi: 10.1080/20018525.2019.1591842. eCollection 2019.
3
Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA).
Arch Bronconeumol. 2017 Aug;53(8):443-449. doi: 10.1016/j.arbres.2017.04.002. Epub 2017 May 8.
4
Bronchial mucosal dendritic cells in smokers and ex-smokers with COPD: an electron microscopic study.
Thorax. 2008 Feb;63(2):108-14. doi: 10.1136/thx.2007.078253. Epub 2007 Sep 17.
5
Comparative prevalence of co-morbidities in smoking and non-smoking asthma patients with incomplete reversibility of airway obstruction, non-smoking asthma patients with complete reversibility of airway obstruction and COPD patients.
Respir Med. 2017 Apr;125:82-88. doi: 10.1016/j.rmed.2017.03.005. Epub 2017 Mar 6.
6
The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?
ERJ Open Res. 2021 Feb 1;7(1). doi: 10.1183/23120541.00768-2020. eCollection 2021 Jan.
7
Asthma and smoking-induced airway disease without spirometric COPD.
Eur Respir J. 2017 May 1;49(5). doi: 10.1183/13993003.02061-2016. Print 2017 May.
8
Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit.
Respir Med. 2013 Sep;107(9):1417-22. doi: 10.1016/j.rmed.2013.04.021. Epub 2013 May 20.
9
The effect of pulmonary rehabilitation on smoking and health outcomes in COPD patients.
Clin Respir J. 2021 Aug;15(8):855-862. doi: 10.1111/crj.13373. Epub 2021 Apr 23.
10
Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States.
Ann Am Thorac Soc. 2016 Jun;13(6):803-10. doi: 10.1513/AnnalsATS.201508-554OC.
引用本文的文献
1
Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study.
Adv Ther. 2025 Jul;42(7):3334-3353. doi: 10.1007/s12325-025-03231-6. Epub 2025 May 19.
2
The Influence of Emphysema on Treatment Response to Biologic Therapy in Severe Asthma.
J Asthma Allergy. 2024 Nov 8;17:1129-1140. doi: 10.2147/JAA.S474306. eCollection 2024.
3
Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study).
J Asthma Allergy. 2023 May 11;16:541-552. doi: 10.2147/JAA.S403286. eCollection 2023.
4
Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD.
ERJ Open Res. 2022 Oct 24;8(4). doi: 10.1183/23120541.00207-2022. eCollection 2022 Oct.
5
Asthma and Tobacco Smoking.
J Pers Med. 2022 Jul 27;12(8):1231. doi: 10.3390/jpm12081231.
本文引用的文献
1
Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2702-2714. doi: 10.1016/j.jaip.2021.01.011. Epub 2021 Jan 21.
2
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
Chest. 2021 Feb;159(2):496-506. doi: 10.1016/j.chest.2020.08.2083. Epub 2020 Aug 31.
3
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.
Eur Respir J. 2020 Oct 15;56(4). doi: 10.1183/13993003.00151-2020. Print 2020 Oct.
4
Comparison of Artificial Intelligence-Based Fully Automatic Chest CT Emphysema Quantification to Pulmonary Function Testing.
AJR Am J Roentgenol. 2020 May;214(5):1065-1071. doi: 10.2214/AJR.19.21572. Epub 2020 Mar 4.
5
Protocol of a Randomized Controlled Study of the PneumRx Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema (ELEVATE).
Respiration. 2019;98(6):512-520. doi: 10.1159/000502100. Epub 2019 Nov 19.
6
Characteristics and treatment regimens across ERS SHARP severe asthma registries.
Eur Respir J. 2020 Jan 9;55(1). doi: 10.1183/13993003.01163-2019. Print 2020 Jan.
7
Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response.
BMC Pulm Med. 2018 Jul 18;18(1):119. doi: 10.1186/s12890-018-0689-2.
8
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.
9
Asthma and smoking-induced airway disease without spirometric COPD.
Eur Respir J. 2017 May 1;49(5). doi: 10.1183/13993003.02061-2016. Print 2017 May.
10
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5.
Zotero 插件